RT Journal Article
SR Electronic
A1 Nichols, Emma Hitt
T1 Spironolactone Misses Primary Endpoint in TOPCAT
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 12
SP 21
OP 22
DO 10.1177/155989771412013
UL http://mdc.sagepub.com/content/14/12/21.2.abstract
AB Spironolactone treatment of heart failure (HF) with preserved ejection fraction (HFpEF) did not significantly reduce cardiovascular death, hospitalization due to HF, or resuscitated cardiac arrest compared with placebo. This article presents updated data from the Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function trial [TOPCAT; Shah SJ et al. Circ Heart Fail 2012].